Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debitai for functional dyspepsia (randomized double-blind placebo-controlled multicenter Phase 4 trial)
ChiCTR2300068489Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional dyspepsia (FD) comparing Debitai arm with Placebo arm (2 arms). Primary endpoint: Improvement rate of main symptoms at 2 weeks. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
bismuth aluminate
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on ChiCTR2300068489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068489.